{
  "id": "601c17c21cb411341a00000e",
  "type": "factoid",
  "question": "The Shingrix vaccine is used to prevent what disease?",
  "ideal_answer": "The Shingrix vaccine is used for prevention of herpes zoster.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32999027",
    "http://www.ncbi.nlm.nih.gov/pubmed/31399377",
    "http://www.ncbi.nlm.nih.gov/pubmed/32862397",
    "http://www.ncbi.nlm.nih.gov/pubmed/31423396",
    "http://www.ncbi.nlm.nih.gov/pubmed/30145235",
    "http://www.ncbi.nlm.nih.gov/pubmed/33163688",
    "http://www.ncbi.nlm.nih.gov/pubmed/33067034",
    "http://www.ncbi.nlm.nih.gov/pubmed/31258310",
    "http://www.ncbi.nlm.nih.gov/pubmed/30370455",
    "http://www.ncbi.nlm.nih.gov/pubmed/32606264",
    "http://www.ncbi.nlm.nih.gov/pubmed/31400911"
  ],
  "snippets": [
    {
      "text": "Postherpetic neuralgia (PHN) is a challenging condition for pain management specialists. The prevention of herpes zoster (HZ) and subsequent PHN in individuals aged 50 years and older, via the development of new vaccines, is an ongoing research project. The live zoster vaccine (LZV, Zostavax\u00ae) was the first proof of concept that vaccination could prevent HZ, but LZV cannot be used in various immunecompromised patients. This led to the development of a new non-live recombinant zoster vaccine (RZV, Shingrix\u00ae). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32606264",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Previously, secondary prevention of herpes zoster required live-attenuated vaccination, which is contraindicated in immunocompromised populations. More recently, a recombinant subunit vaccine (Shingrix, GlaxoSmithKline, Research Triangle Park, North Carolina) was approved by the Food and Drug Administration.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33163688",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SHINGRIX, a non-live recombinant herpes zoster vaccine, was approved by the Food and Drug Administration in 2017.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33067034",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recombinant Zoster Vaccine (Shingrix) to Prevent Herpes Zoster.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30145235",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Two different vaccines have been developed to prevent HZ; one is based on a live attenuated VZV strain (Zostavax), and the other is based on adjuvanted gE recombinant protein (Shingrix).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32999027",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Shingrix is a new attenuated subunit vaccine for Varicella Zoster Virus with an AS01B adjuvant that can result in a potent immune response.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31423396",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In October 2017, the U.S. Food and Drug Administration approved recombinant zoster vaccine under the brand name Shingrix to prevent herpes zoster.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30145235",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: The adjuvanted recombinant zoster vaccine (Shingrix) can prevent herpes zoster in older adults and autologous haemopoietic stem cell transplant recipients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31399377",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ctober 2017, the US Centers for Disease Control and Prevention Advisory Committee on Immunization Practices recommended the adjuvanted recombinant zoster vaccine (RZV; Shingrix, GSK) as the preferred vaccine for preventing herpes zoster (HZ) and related complications in immunocompetent adults aged \u2265\u00a050 years. Subsequentl",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32862397",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Zoster vaccine live (ZVL [Zostavax]) has been recommended for the prevention of herpes zoster (HZ) among immunocompetent adults \u226560\u202fyears in the United States since 2008. To exa",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31400911",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " The subunit vaccine is approved for the prevention of herpes zoster (HZ) [EU, USA, Japan, Canada and Australia] and postherpetic neuralgia (PHN) [EU and Australia] in adults aged\u2009\u2265\u200950\u00a0years. In the pivo",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30370455",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "x is a new attenuated subunit vaccine for Varicella Zoster Virus with an AS01B adjuvant that can result in a potent immune response. The Shi",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31423396",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ctober 2017, the US Centers for Disease Control and Prevention Advisory Committee on Immunization Practices recommended the adjuvanted recombinant zoster vaccine (RZV; Shingrix, GSK) as the preferred vaccine for preventing herpes zoster (HZ) and related complications in immunocompetent adults aged \u2265\u00a050 years. Subseque",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32862397",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " The subunit vaccine is approved for the prevention of herpes zoster (HZ) [EU, USA, Japan, Canada and Australia] and postherpetic neuralgia (PHN) [EU and Australia] in adults aged\u2009\u2265\u200950\u00a0years. In the p",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30370455",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Zoster vaccine live (ZVL [Zostavax]) has been recommended for the prevention of herpes zoster (HZ) among immunocompetent adults \u226560\u202fyears in the United States since 2008. To ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31400911",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Women ages 50 years and older are at risk for herpes zoster, a reactivated virus from varicella zoster virus (chickenpox) that causes a painful vesicular rash and can result in postherpetic neuralgia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30145235",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: The adjuvanted recombinant zoster vaccine (Shingrix) can prevent herpes zoster in older adults and autologous haemopoietic stem cell transplant",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31399377",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Shingrix, a new vaccine for herpes zoster.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31258310",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Shingrix: A New Herpes Zoster Vaccine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31258310",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [],
  "exact_answer": "Postherpetic neuralgia, also known as Shingles, herpes zooster"
}